Compare International Business Machines Corp (IBM) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Business Machines Corp vs Johnson & Johnson — how do they compare? International Business Machines Corp trades at $226.67 (market cap $213.50B), while Johnson & Johnson trades at $261.43 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 2.9× International Business Machines Corp's market cap, and International Business Machines Corp pays the higher dividend (2.98%). Which is the better fit depends on your goals — on Pluang, investors hold International Business Machines Corp for 88 Days and Johnson & Johnson for 129 Days on average.
| IBM | JNJ | |
|---|---|---|
Market Cap | $213.50B | $618.09B |
Volume | 8,908,687 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $329.23 | $278.43 |
52-Week Low | $205.77 | $186.00 |
Typical Hold Time | 88 Days | 129 Days |
Enterprise Value | $270.64B | $646.37B |
Dividend Yield | 2.98% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBM stock trades at $227.13, up 3.0% today, showing resilience after recent volatility. The company reported strong Q4 2025 and Q1 2026 earnings beats but missed Q2 2026 expectations. Revenue growth accelerated to $67.54B in 2025 with net income margin improving to 15.52%. Technical indicators show bearish momentum with RSI at 71.56 suggesting overbought conditions, while analyst consensus remains positive with a $255.50 price target.
IBM's pivot to hybrid cloud and AI consulting shows promise with $5.5B generative AI bookings, though execution risks persist. The stock offers 12.5% upside to consensus target but faces headwinds from mainframe cyclicality and competitive pressure. Cash flow trends weakened in 2025 with negative net cash flow, requiring monitoring of capital allocation strategy.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
